DNA methylation as a biomarker for neuropsychiatric diseases.
ABSTRACT DNA methylation, which has been investigated extensively recently, has been studied in various human diseases, including cancer, and the analysis of DNA methylation has provided useful biomarkers for diagnosing cancer, monitoring treatment, and predicting the prognosis of cancer. Recently, aberrant DNA methylation has been reported in various neuropsychiatric diseases in both postmortem brains and peripheral blood cells. This review summarizes the current evidence on aberrant DNA methylation in peripheral blood cells from patients with neurodevelopmental, neurodegenerative, and psychiatric disorders, and we propose that DNA methylation could be a novel biomarker for these disorders.